

## Pro und Contra, pro and contra, review articles and personal views

Ein **Interessenkonflikt** im weiteren Sinn oder ein **Zielkonflikt** liegt vor, wenn eine Situation dem Einfluss von einander widerstrebenden Faktoren unterliegt und zwischen ihnen *ausgewogen* reguliert werden soll. Quelle: <http://de.wikipedia.org/wiki/Interessenkonflikt>

Umstände von denen ein bedeutsames Risiko einer Beeinflussung des professionellen Urteils ausgeht.

A **conflict of interest (COI)** occurs when an individual or organization is involved in multiple interests, one of which could possibly corrupt the motivation for an act in another.

Source: [http://en.wikipedia.org/wiki/Conflict\\_of\\_interest](http://en.wikipedia.org/wiki/Conflict_of_interest) <http://www.bmj.com/content/347/bmj.f5535>

Circumstances that pose a significant risk of influencing the professional judgment.

**MIQ 12 Lyme-Borreliose** (2000) Wilske BZ, Brade V, Eiffert M, Göbel UB, Stanek G. unter Mitarbeit von H. W. Pfister. in: Mauch, H.; Lütticken, R.; Gatermann, S., im Auftrag der Deutschen Gesellschaft für Hygiene und Mikrobiologie (DGHM). (eds.) Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik. Urban & Fischer Verlag, München Jena 1-59.

<http://shop.elsevier.de/978-3-437-41582-1>

**ILADS Leitlinien:** Daniel Cameron, Andrea Gaito, Basking Ridge, Nick Harris, Gregory Bach, Sabra Bellovin, Kenneth Bock, Steven Bock, Joseph Burrascano, Constance Dickey, Richard Horowitz, Steven Phillips, Laurence Meer-Scherrer, Bernard Raxlen, Virginia Sherr, Harold Smith, Pat Smith, Raphael Stricker (2004) **The International Lyme and Associated Diseases Society Evidence-based guidelines for the management of Lyme-disease.** Future Drugs Ltd. All rights reserved. ISSN 1478-7210 Expert Rev. Anti-infect. Ther. 2(1) [http://www.ilads.org/lyme/ILADS\\_Guidelines.pdf](http://www.ilads.org/lyme/ILADS_Guidelines.pdf)

**IDSA Leitlinien:** [Gary P. Wormser](#), [Raymond J. Dattwyler](#), [Eugene D. Shapiro](#), [John J. Halperin](#), [Allen C. Steere](#), [Mark S. Klempner](#), [Peter J. Krause](#), [Johan S. Bakken](#), [Franc Strle](#), [Gerold Stanek](#), [Linda Bockenstedt](#), [Durland Fish](#), [J. Stephen Dumler](#), [Robert B. Nadelman](#) (2006) **The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America** Clin Infect Dis. 43 (9), 1089-1134. doi: 10.1086/508667 <http://cid.oxfordjournals.org/content/43/9/1089.full>

**Die IDSA Leitlinien zu Lyme-Borreliose aus dem Jahr 2006 wurden von den meisten etablierten europäischen Organisationen übernommen.**

**The IDSA guidelines on Lyme disease from 2006 have been adopted by most of the established European organizations.**

**„Bitte bedenken Sie aber. Die IDSA Leitlinien sind nur gedacht als „Startrampe“ für Impfstoffe. Deshalb wurden sie konstruiert. Es gibt keinen anderen Grund“. Quelle: Sat, Aug 10, 2013 at 11:33 PM, Lynn Shepler.**

**„Keep in mind that the IDSA guidelines are simply a launching pad for vaccines. That is why they were constructed. No other reason“. Source: Sat, Aug 10, 2013 at 11:33 PM, by Lynn Shepler.**

**Die IDSA-Leitlinien aus dem Jahr 2006 stehen in Kollision zu den Erfahrungen aus der ambulanten ärztlichen Praxis (sog. LLD = Lyme literate Doctors, ILADS, DBG).**

**The IDSA guidelines from 2006 are in conflict with the experience of the physician-patient practice (so-called LLD = Lyme literate Doctors, ILADS, DBG).**

Schott G, Dünneberger C, Mühlbauer B, Niebeling W, Pacht H (2013) Besteht ein Einfluss pharmazeutischer Unternehmen auf Leitlinien? Deutsches Ärzteblatt 110(35-36), 575-584

Ludwig W-D (2013) Der Einfluss pharmazeutischer Unternehmen auf ärztliche Leitlinien. Eine Expertise der Arzneimittelkommission der deutschen Ärzteschaft <http://www.akdae.de/Stellungnahmen/Weitere/20120123.pdf>

**Die IDSA-Leitlinien aus dem Jahr 2006 wurden im Jahr 2016 aus dem nationalen Leitlinienregister (NGC) entfernt. Quelle: <http://www.guideline.gov/>**

**The IDSA guidelines from 2006 were removed in 2016 from the National Guideline Clearinghouse (NGC). Source: <http://www.guideline.gov/>**

Gilles D (2011) Parliamentary business. **Peer review.**

<http://www.publications.parliament.uk/pa/cm201011/cmselect/cmsctech/writev/856/m22.htm>

**Leitlinie Neuroborreliose** (2008) Rauer S, Kaiser R, Kölmel HW, Pfister HW, B. Wilske B  
Herausgegeben von der Kommission Leitlinien der Deutschen Gesellschaft für Neurologie -  
Expertengruppe Neuroborreliose. **AWMF gelistet.:** 1-15

<http://www.borreliose.me/mediapool/77/776837/data/dgnborr.pdf>

**Leitlinien der Deutschen Dermatologischen Gesellschaft.** AWMF Leitlinien Hofmann H,  
Bruckbauer H, Fingerle V, Mempel M, Müllegger RR, Plettenberg A, Simon M, Wallich R (2009)  
Kutane Manifestationen der Lyme Borreliose. <http://leitlinien.net/>.

Lo B, Field MJ (2009) **Conflict of Interest** in Medical Research, Education, and Practice. The National  
Academies Press Washington DC, <http://www.ncbi.nlm.nih.gov/books/NBK22942/pdf/TOC.pdf>  
<http://www.ncbi.nlm.nih.gov/books/NBK22926/>

**7 Conflicts of Interest** and Development of Clinical Practice Guidelines. (2009) National Academy of  
Sciences. <http://www.ncbi.nlm.nih.gov/books/NBK22928/>

**Infectious Diseases Society of America practice guidelines for clinical assessment, treatment  
and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis.** 2000 Jul  
(revised 2006 Jun; reaffirmed 2010). NGC:005085

Infectious Diseases Society of America - Medical Specialty Society

Stanek G, Fingerle V, Hunfeld KP, Jaulhac B, Kaiser R, Krause A, Kristoferitsch W, O'Connell S,  
Ornstein K, Strle F, Gray J (2010) **Lyme borreliosis: Clinical case definitions for diagnosis and  
management in Europe.** <http://www.ncbi.nlm.nih.gov/pubmed/20132258>

**EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis**  
(2010) Mygland A, Ljostad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I. Eur J Neurol 17,  
8-16, e11-14.

[http://www.efns.org/fileadmin/user\\_upload/guideline\\_papers/EFNS\\_guideline\\_2010\\_European\\_lyme\\_neuroborreliosis.pdf](http://www.efns.org/fileadmin/user_upload/guideline_papers/EFNS_guideline_2010_European_lyme_neuroborreliosis.pdf)

**DBG Leitlinien:** (2011) **Diagnostik und Therapie der Lyme-Borreliose.** Deutsche Borreliose  
Gesellschaft. <http://www.borreliose-gesellschaft.de/de/Leitlinien>

An der Konsensusbildung haben sich beteiligt: RÜDIGER VON BAEHR, WILDERICH BECKER, HARALD  
BENNEFELD, WALTER BERGHOF, UTA EVERTH, HANS-PETER GABEL, NADJA EL-MAHGARY,  
WERNER GROßMANN, WOLFGANG HEESCH, DOROTHEA HILLSCHER, PETRA HOPF-SEIDEL, BERNT-  
DIETER HUISMANS, WOLFGANG KLEMMANN, MICHAEL KRAHL, BERND KRONE, JÖRG MERKEL, KURT  
E. MÜLLER, UWE NEUBERT, CARSTEN NICOLAUS, OLIVER NOLTE, DIETRICH ROSIN, ARMIN  
SCHWARZBACH, CORD UEBERMUTH, BARBARA WEITKUS, „**Potentielle Interessenkonflikte:**

**Die Autoren sind niedergelassene Ärzte in eigenen Praxen, arbeiten für ein medizinisches Labor, eine  
Klinik oder sind im Ruhestand. Darüber hinaus gibt es keine wirtschaftlichen Interessen, die für die  
Erstellung der Leitlinien relevant gewesen sind. Politische, akademische (z.B. Zugehörigkeit zu  
bestimmten „Schulen“) oder wissenschaftliche Interessenkonflikte bestehen nicht.“**

Paul G Auwaerter, Johan S Bakken, Raymond J Dattwyler, J Stephen Dumler, John J Halperin,  
Edward McSweeney, Robert B Nadelman, Susan O'Connell, Eugene D Shapiro, Sunil K Sood,  
Allen C Steere, Arthur Weinstein, Gary P Wormser (2011) **Personel view. Antiscience and  
ethical concerns associated with advocacy of Lyme disease.** Lancet Infect Dis. 11, 713–19

<http://www.ncbi.nlm.nih.gov/pubmed/21867956>

[http://www.healthunit.org/hazards/documents/Advocacy\\_of\\_Lyme\\_Disease.pdf](http://www.healthunit.org/hazards/documents/Advocacy_of_Lyme_Disease.pdf)

**“Conflicts of interest**

**PGA** has served as a consultant for Oxford Diagnostics and has participated in expert testimony in two medicolegal  
suits about possible Lyme disease. He has equity interest in Johnson & Johnson, no products of which are referred to  
in this article. **RJD** is part owner of and has stock in Biopeptides Corporation, no product of which is referred to in this  
article, has received payment for providing expert testimony in malpractice cases and holds patents on vaccine and  
diagnostic technology with SUNY at Stony Brook Biopeptides. **JSD** has received support for travel to meetings from  
DiaSorin and has licence of US patent 5,955,359 to Focus Diagnostics; none of these declarations are directly

related to the contents of this article. **JJH** has served as an expert witness in several medicolegal cases concerning Lyme disease and has equity in Abbott, Bristol-Myers Squibb, Johnson & Johnson, and Merck; no products from these companies are referred to in this article. **EMcS** was a former programme officer for Lyme disease at the US NIH. RBN has served as an expert witness in malpractice litigation involving Lyme disease. **EDS** is a board member of the American Lyme Disease Foundation, for which no compensation is received. He has reviewed medical records for the Metropolitan Life Insurance Company and has provided medicolegal testimony. **GPW** is a board member of the American Lyme Disease Foundation for which no compensation is received, has served as an expert witness in malpractice cases involving Lyme disease, has research grants from the NIH/Immunetics, BioRad, DiaSorin, and BioMerieux to study diagnostic tests for Lyme disease, none of which is mentioned in the manuscript, and has equity in Abbott, a company not known to have any approved product for Lyme disease. **JSB, RJD, JSD, JJH, RBN, EDS, ACS,** and **GPW** have served on the panel for the 2006 IDSA Lyme disease guidelines. **JSB, SO'C, SKS, ACS,** and **AW** declare that they have no conflicts of interest".

Institute of Medicine (2011) **Clinical Practice Guidelines we can trust.**

<http://www.iom.edu/~media/Files/Report%20Files/2011/Clinical-Practice-Guidelines-We-Can-Trust/Clinical%20Practice%20Guidelines%202011%20Report%20Brief.pdf>

Norris SL, Holmer HK, Ogden LA, Burda BU (2011) **Conflict of Interest** in Clinical Practice Guideline Development: A Systematic Review. PLOS one 6(10), e25153

<http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0025153>

Stretch D, Klemperer D, Knüppel H, Kopp I, Meyer G, Koch K, (2011) Deutsches Netzwerk Evidenzbasierte Medizin. **Interessenkonfliktregulierung:** Internationale Entwicklung und offene Fragen. Ein Diskussionspapier. view (last access on 7 February 2013).

<http://www.ebm-netzwerk.de/was-wir-tun/pdf/interessenkonfliktregulierung-2011.pdf>

**Neuroborreliose. Leitlinie Entwicklungsstufe: S1** Stand: September 2012 Gültig bis: 2015 AWMF-Registernummer: 030/071 Clinical Pathway COI-Erklärung. Federführend: Prof. Dr. S. Rauer, Freiburg, [sebastian.rauer@uniklinik-freiburg.de](mailto:sebastian.rauer@uniklinik-freiburg.de). 10.09.2015: Gültigkeit nach Überprüfung durch das LL-Sekretariat verlängert bis 29.09.2017.

[http://www.awmf.org/uploads/tx\\_szleitlinien/030-071\\_S1\\_Neuroborreliose\\_2012\\_verlaengert.pdf](http://www.awmf.org/uploads/tx_szleitlinien/030-071_S1_Neuroborreliose_2012_verlaengert.pdf)

Langer T, Conrad S, Fishman L, Gerken M, Schwarz S, Weikert B, Ollenschläger G, Weinbrenner S (2012) **Interessenkonflikte** bei Autoren medizinischer Leitlinien: Eine Analyse der Leitlinien deutscher Fachgesellschaften 2009-2011. Dtsch Arztebl Int 109(48): 836-42; DOI: 10.3238/arztebl.2012.0836

<http://www.aerzteblatt.de/archiv/132916/Interessenkonflikte-bei-Autoren-medizinischer-Leitlinien-Eine-Analyse-der-Leitlinien-deutscher-Fachgesellschaften-2009-2011>

Langer T, Conrad S, Fishman L, Gerken M, Schwarz S, Weikert B, Ollenschläger G, Weinbrenner S (2012) **Conflicts of interest** among authors of medical guidelines – an analysis produced by German specialist societies. Dtsch Arztebl Int 109(48), 836-42 <http://www.ncbi.nlm.nih.gov/pubmed/23248714> **"From 2011 onward, all conflict-of-interest declarations by guideline authors have been published in the AWMF database. There is no current standard for the evaluation and management of conflicts of interest in guideline-creating groups, and this situation urgently needs to be remedied."**

Norris SL, Holmer HK, Burda BU, Ogden LA, Fu R (2012) **Conflict of Interest** Policies for Organizations Producing a Large Number of Clinical Practice Guidelines. PLoS ONE 7(5): e37413. doi:10.1371/journal.pone.0037413 <http://www.plosone.org/article/info:doi/10.1371/journal.pone.0037413>

Auwaerter PG et al. (2012) **Bullying Borrelia:** When the culture of science is under attack. Transactions of the American Clinical and Climatological Association Vol. 123

<http://www.ncbi.nlm.nih.gov/pubmed/23303970>

Ferguson J (2012) **Cure Unwanted? Exploring the Chronic Lyme Disease Controversy** and Why **Conflicts of Interest in Practice Guidelines May Be Guiding Us the wrong Way.** American Journal of Law and Medicine. 38, 196-224

<http://business.highbeam.com/42/article-1G1-283022008/cure-unwanted-exploring-chronic-lyme-disease-controversy>

**"We can't treat conflicts of interest like some family secret no one talks about. We must become more comfortable asking and answering pertinent questions about the sources and substance of industry funding that might influence individuals, institutions, and organizations."**

Jones DJ, Barkun AN, Lu Y (2012) **Conflicts of Interest** Ethics: Silencing Expertise in the Development of International Clinical Practice Guidelines. Ann Intern Med. 156(11), 809-816

<http://annals.org/article.aspx?articleid=1170881>

Eccles MP, Grimshaw JM, Shekelle P, Schünemann HJ, Woolf S (2012) Methodology. Developing clinical practice guidelines: target audiences, identifying topics for guidelines, guideline group composition and functioning and **conflicts of interest**. Implementation Science 2012, 7, 60 doi:10.1186/1748-5908-7-60 <http://www.implementationscience.com/content/7/1/60>  
[http://www.rand.org/pubs/external\\_publications/EP51260.html](http://www.rand.org/pubs/external_publications/EP51260.html)

Huppertz HI, Bartmann P, Heininger U, Fingerle V, Kinet M, Klein R, Korenke GC, Nentwich HJ. (2012) Rational diagnostic strategies for Lyme borreliosis in children and adolescents: **recommendations by the Committee for Infectious Diseases and Vaccinations of the German Academy for Pediatrics and Adolescent Health**. Eur J Pediatr. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491193/>

HUPPERTZ HI, TZARIBACHEV N (2013) **Leitlinie der Gesellschaft für Kinder- und Jugendrheumatologie und der Deutschen Gesellschaft für Kinder- und Jugendmedizin Lyme-Arthritis** [http://www.awmf.org/uploads/tx\\_szleitlinien/027-056I\\_S1\\_Lyme\\_Arthritis\\_2013-01.pdf](http://www.awmf.org/uploads/tx_szleitlinien/027-056I_S1_Lyme_Arthritis_2013-01.pdf)

Halperin JJ et al. (2013) **Review. Common Misconceptions About Lyme Disease**. The American Journal of Medicine. 126(3), 264.e1-7. doi: 10.1016/j.amjmed.2012.10.008. Epub 2013 Jan 12. <http://www.ncbi.nlm.nih.gov/pubmed/23321431>

Muche-Borowski C, Selbmann HK, Nothacker M, Müller W, Kopp I (2013) Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Ständige Kommission Leitlinien: **AWMF-Regelwerk Leitlinien**. <http://www.awmf.org/leitlinien/awmf-regelwerk.html>  
„**Prof. Kopp hat Beraterhonorare von der Firma Pharmallergan erhalten (bis 2010)**“ Quelle: Deutsches Ärzteblatt110(16), 287

Fingerle V, Hautmann W et al. (2013) **BLÄK informiert: Klinik, Diagnostik und Therapie der Lyme-Borreliose**. Bayerisches Ärzteblatt 4, 162-165  
[http://www.blaek.de/presse/aerzteblatt/2013/BAB\\_4\\_2013\\_162\\_165.pdf](http://www.blaek.de/presse/aerzteblatt/2013/BAB_4_2013_162_165.pdf)  
[http://www.blaek.de/docs/presse/literatur/BLAEK\\_Borreliose\\_Literatur.pdf](http://www.blaek.de/docs/presse/literatur/BLAEK_Borreliose_Literatur.pdf)

Klempner MS, Baker PJ, Shapiro ED, Marques A, Dattwyler RJ, Halperin JJ, MD, Wormser GP (2013) Review: **Treatment Trials for Post-Lyme Disease Symptoms Revisited**. The American Journal of Medicine. Vol -, No -, 1-5 <http://www.ncbi.nlm.nih.gov/pubmed/23764268>  
“**Conflict of Interest: MSK has received research grants from the Centers for Disease Control and Prevention and the National Institutes of Health. PJB has no conflicts of interest. EDS is a board member of the American Lyme Disease Foundation, for which no compensation is received, and has received compensation from UpToDate for reviewing medical records for the Metropolitan Life Insurance Company and for providing medicolegal testimony. AM is co-inventor on a patent application for a test for the detection of anti-Borrelia burgdorferi antibodies in which one of the antigens is based on the IR6 peptide: VOVO LIPS test for Lyme disease US Provisional Application No. 61/312,520 filed March 10, 2010 (HHS Reference No. E-036-2010/0-US-01). No money has been paid to her or to her institution. She is supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, and National Institutes of Health (NIH). RJD has received research grants from the NIH; is part owner of and has stock in Biopeptides Corp, no product of which is referred to in this article; has received payment for providing expert testimony in malpractice cases; and holds patents on vaccine and diagnostic technology with SUNY at Stony Brook and Biopeptides Corp. JJH has served as an expert witness in several medicolegal cases concerning Lyme disease and has equity in Abbott Laboratories, Bristol-Myers Squibb, Johnson & Johnson, and Merck; no products from these companies are referred to in this article. GPW has received research grants from the Centers for Disease Control and Prevention, the NIH, Immunefies, Inc, BioRad, DiaSorin, Inc, and bioMérieux, Inc; holds equity in Abbott Laboratories; is an expert witness in malpractice cases involving Lyme disease; is an unpaid board member of the American Lyme Disease Foundation; was an expert witness regarding Lyme disease in a disciplinary action for the Missouri Board of Registration for the Healing Arts; and is a consultant to Baxter for Lyme vaccine development.**”

Nolte O, Berghoff W, v. Baer V, Müller K (2013) **Borreliose. Klinik, Diagnostik, Therapie**. Umwelt . Medizin . Gesellschaft. 3, 151-235 <http://www.umg-verlag.de/umwelt-medizin-gesellschaft/cont3-13.pdf>

Lantos PM, Auwaerter PG, Wormser GP (2013) A Systematic Review of **Borrelia burgdorferi Morphologic Variants Does Not Support a Role in Chronic Lyme Disease**. Clin Infect Dis. <http://cid.oxfordjournals.org/content/early/2013/12/12/cid.cit810.abstract>  
“**In the context of the broader medical literature it is not currently possible to ascribe a pathogenic role to morphologic variants of B. burgdorferi in either typical manifestations of Lyme disease or in other**

**chronic disease states that are often labeled chronic Lyme disease. There is no clinical literature to justify specific treatment of B. burgdorferi morphologic variants”.**

<http://relative-risk.blogspot.de/2013/12/the-shifting-shape-of-chronic-lyme.html>

Cameron DJ, Johnson LB, Maloney EL (2014) Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev. Anti Infect. Ther. 12(9), 1103-1135  
[http://www.tandfonline.com/doi/full/10.1586/14787210.2014.940900](http://www.tandfonline.com/doi/full/10.1586/14787210.2014.940900#aHR0cDovL3d3dy50YW5kZm9ubGluZS5jb20vZG9pL3BkZi8xMC4xNTg2LzE0Nzg3MjEwLjIwMTQuOTQwOTAwP25lZWRYBY2Nlc3M9dHJ1ZUBAQDA=)  
<http://informahealthcare.com/doi/pdf/10.1586/14787210.2014.940900>

Nemeth J, Bernasconi E, Heininger U et al. (2016) Update of the Swiss guidelines on post-treatment Lyme disease syndrome. Swiss Med Wkly. 146:w14353. doi: 10.4414/smw.2016.14353. eCollection 2016. <https://www.ncbi.nlm.nih.gov/pubmed/27922168>  
<http://www.smw.ch/content/smw-2016-14353/>

➔ **National Guideline Clearinghouse, Guidelines Lyme disease**  
<http://www.guideline.gov/search/search.aspx?term=lyme+disease>

## **Regelwerke zur Erstellung und Formulierung von medizinischen Leitlinien. Rules for the creation and formulation of clinical guidelines.**

Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2010) Programm für Nationale VersorgungsLeitlinien. Methoden-Report. 4<sup>th</sup> edition.  
[http://www.versorgungsleitlinien.de/methodik/pdf/nvl\\_methode\\_4.aufli.pdf](http://www.versorgungsleitlinien.de/methodik/pdf/nvl_methode_4.aufli.pdf)

Lomotan EA, Michel G, Lin Z, Shiffman RN. (2010) How “should” we write guideline recommendations? Interpretation of deontic terminology in clinical practice guidelines: survey of the health services community. Qual Saf Health Care 19, 509–13. [CrossRef](#) [PubMed Central](#)

Lee DH, Vielemeyer O (2011) **Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines.** Arch Intern Med. 171(1), 18-22  
<http://www.ncbi.nlm.nih.gov/pubmed/21220656>  
<http://archinte.jamanetwork.com/article.aspx?articleid=226373>

Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)-Ständige Kommission Leitlinien: AWMF-Regelwerk “Leitlinien”. 1<sup>st</sup> edition 2012.  
<http://www.awmf.org/leitlinien/awmf-regelwerk/awmf-regelwerk-offline.html>

Nast A, Sporbeck B, Jacobs A, Erdmann R, Roll S, Sauerland U, Rosumeck S (2013) Study of perceptions of the extent to which guideline recommendations are binding—a survey of commonly used terminology. Dtsch Arztebl Int 110(40), 663–8. DOI: 10.3238/arztebl.2013.0663  
<http://www.aerzteblatt.de/archiv/147059/Wahrnehmung-der-Verbindlichkeit-von-Leitlinienempfehlungen-Eine-Umfrage-zu-haeufigen-Formulierungen>

**DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES** (2013)  
<http://resources.iom.edu/widgets/systematic-review/infographic.html>

[How to decide whether a clinical practice guideline is trustworthy](#) (2013) JAMA: the journal of the American Medical Association

## **Experten - Beiträge**

Berghoff W (2014) Stellungnahme zu den Leitlinien der DGN:

[http://www.praxis-berghoff.de/dokumente/Urteile\\_OLG\\_Muenchen\\_und\\_OLG\\_Koeln\\_aus\\_2013.pdf](http://www.praxis-berghoff.de/dokumente/Urteile_OLG_Muenchen_und_OLG_Koeln_aus_2013.pdf)

Hübner A (2014) Gedanken und Fragen eines Klinikers zur Infektion mit Borrelien und Ko-Infekten  
<http://www.grin.com/de/e-book/282739/gedanken-und-fragen-eines-klinikers-zur-infektion-mit-borrelien-und-ko-infekten>

Huismans BD (2014) Die kleine Diagnostik-Therapie-Fibel bei Borrelien und Ko-Infekten für Kliniker und Praktiker. Aus dem Internet. Tabellen, Kommentare, Literatur.  
<http://www.grin.com/de/e-book/283084/die-kleine-diagnostik-therapie-fibel-bei-borrelien-und-ko-infekten-fuer>

Hübner A, Huismans BD (2016) Thoughts and questions of a clinician related to the infection with borrelia and co-infections. <http://tinyurl.com/zjm7gle> (Deutsch entspr.) <http://tinyurl.com/okf2zzx>  
<http://www.grin.com/en/e-book/313377/thoughts-and-questions-of-a-clinician-related-to-the-infection-with-borrelia>

Huismans BD (2016) Ko-Erreger und Toxine bei Lyme – Borreliose, Multi-System – Multi-Infektions – Krankheiten und bei Cavete Diagnosen. <http://www.xerlebnishaft.de/ko-erreger.pdf>

Berghoff W (2016) Lehrbuch Lyme-Borreliose. Verlag Berghoff.  
<http://www.praxis-berghoff.de/dokumente/LEHRBUCH-Lyme-Borreliose.pdf>

Huismans BD (2017) Co-pathogens and toxins in Lyme disease, Multi-system – Multi-infektion – diseases and in cavete diagnoses. [http://www.kabilahsystems.de/ko-erreger\\_eng.pdf](http://www.kabilahsystems.de/ko-erreger_eng.pdf)

## Beiträge von Patienten-Organisationen

Borreliose und FSME Bund Deutschland. **Manifest Nr.2 (2013)** gegen das Urteil des Oberlandesgerichts München AZ.: 25 U 2548/12, 4 O 265/11 LG Passau verkündet am 17.05.2013  
<http://www.google.de/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CDAQFjAA&url=http%3A%2F%2Fwww.bfbd.de%2Fde%2Fbund%2F1.html%3FcmsDL%3Db028e527a178c176737c2c9ee8cfe3f7&ei=5l1fU-euK4SHtQbmnoAg&usq=AFQjCNG-bkFYNbeqjIQcQZdvG0XncFJ0g&bvm=bv.65636070,d.Yms>

- ➔ **Standpunkte und Perspektiven** [http://www.xerlebnishaft.de/standpunkte\\_perspektiven.pdf](http://www.xerlebnishaft.de/standpunkte_perspektiven.pdf).
- ➔ **Biowaffen, Bio-engineering** <http://www.xerlebnishaft.de/biowaffen.pdf>

[Bernt - Dieter Huismans](#), Last revision Februar 2017 [www.Huismans.click](http://www.Huismans.click)



Back to top: [http://www.erlebnishaft.de/pro\\_contra.pdf](http://www.erlebnishaft.de/pro_contra.pdf)